Kirkland & Ellis advised AbbVie Inc. in its $63 billion cash and stock purchase of Botox-maker Allergan Inc., which was represented by Wachtell in one of the largest mergers in the pharmaceutical industry this year.
The merger will allow AbbVie, maker of top-selling rheumatoid arthritis injection Humira, to diversify its market portfolio. The deal would create a combined company with about $48 billion in sales, making it one of the biggest companies in the healthcare industry.
The deal is expected to close in early 2020.
Kirkland has represented Chicago-based AbbVie in a variety of matters over the years. Most recently ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.